The drug from coronavirus “Replevin” demonstrated high efficiency in the fight against novel coronavirus infection. It is reported TASS with reference to the press service of the company-manufacturer “Promomed”.
“the Drug has demonstrated high efficacy — more than 90 percent. During the first 24 hours, 70 percent of patients with coronavirus infection was felt a radical change of state that in the next few days was confirmed by tests. 80 percent of patients recovered on monotherapy, without concomitant medications. The studies not registered any case of transfer of disease to a more serious phase,” the statement said.
The drug has efficacy against RNA viruses, including coronavirus. It blocks the replication of the virus in human cells, preventing the spread of infection.
The manufacturer also notes that Russia has a more global study of favipiravir than in Japan. Russian companies have expressed readiness to cooperate with Japanese colleagues and specialists from other countries for further studies of the drug.
“We are also interested in participating in research programmes with who and other”, — emphasized in “Promenade”.
On 8 July the Ministry of health has approved the drug from coronavirus “coronaves the” company “R-FARM”, made on the basis of favipiravir.
25 June it was reported that the Ministry of health of Russia approved “Replevin”. According to the register, “Replevin” — the trade name of the drug, and or modified international nonproprietary or chemical name — “Favipiravir”. The drug is produced by company “Promomed” on the basis of favipiravir.
